close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fidelity MSCI Health Care Index ETF (NY:FHLC)

80.73 -0.70 (-0.87%)
Delayed Quote Updated: 2:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fidelity MSCI Health Care Index ETF

< Previous 1 2 Next >
News headline image
Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech ↗
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗
VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure? ↗
FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own. 
Via The Motley Fool
Topics ETFs
FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report ↗
Via Stocktwits
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study ↗
Via Stocktwits
BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later ↗
Via Stocktwits
News headline image
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? ↗
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? ↗
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗
Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus ↗
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility. 
Via The Motley Fool
Topics ETFs
News headline image
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors? ↗
Here's how Invesco's concentrated pharma play compares to Fidelity's diversified approach to healthcare stocks. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? ↗
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK? ↗
Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗
FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH? ↗
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings. 
Via The Motley Fool
Topics ETFs
News headline image
XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio? ↗
State Street's concentrated 60-stock approach outpaced Fidelity's broader 365-holding fund over five years, though both charge identical 0.08% fees. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC? ↗
One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗
One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility. 
Via The Motley Fool
Topics ETFs
News headline image
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗
Compare fees, diversification, and risk between these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value? ↗
Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors. 
Via The Motley Fool
Topics ETFs
News headline image
FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026? ↗
Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story. 
Via The Motley Fool
Topics ETFs
News headline image
Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV ↗
Expense ratios match, but portfolio breadth, yield, and stock concentration set these two healthcare ETFs apart for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations ↗
A federal court blocked NIH's policy capping indirect cost rates on research grants, ruling it unlawful. The decision safeguards billions in funding and ongoing clinical trials. 
Via Benzinga
News headline image
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst ↗
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
News headline image
ETFs In Focus Post UnitedHealth's Mixed Q4 Results ↗
UnitedHealth Group, the largest U.S. health insurer, reported mixed fourth-quarter 2024 results. Shares of the stock dropped nearly 6% on the day following the results. This put various ETFs in the... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
What Lies In Store For Healthcare ETFs In Q3 Earnings? ↗
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
News headline image
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups ↗
A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments. 
Via Benzinga
News headline image
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs ↗
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.